Tubulis raises €60.0M Series B round

The capital will be used to advance the company's proprietary pipeline of antibody-drug conjugates (ADCs) towards clinical evaluation, introduce programs addressing solid tumor indications, and innovate novel payload classes and cancer targets.

Source: https://www.tubulis.com/tubulis-closes-e60-million-series-b-financing-to-accelerate-its-adc-pipeline-and-expand-its-breadth-of-platform-technologies/